Unlocking the Future of Cell and Gene Therapies: Matica Bio Welcomes Paul Kim as CEO

At Matica Bio, a renowned contract development and manufacturing organization (CDMO) specializing in cell and gene therapies (CGTs), a significant change in leadership is set to propel the company to new heights. With the appointment of industry veteran Paul Kim as Chief Executive Officer (CEO), Matica Bio is poised to further expand its capacity and capabilities in the United States and Korea. This strategic move comes as the company aims to revolutionize the CGT industry with its bespoke approach to manufacturing and cutting-edge technologies.

Paul Kim brings with him an impressive track record of nearly thirty years in the CDMO, CRO, and R&D biopharma sectors. Having held esteemed positions such as CEO, Managing Director, Chief Business Officer, Managing Partner, and Executive Board Member at world-renowned organizations including WCCT Global, Genopis, Cobra Biologics, Cognate BioServices, and Novartis Venture Fund, Kim's expertise is unparalleled. He also led the first global biotech fund focusing on innovative Asian biotech investments at Novartis Venture Fund.

Notably, Kim is the visionary behind Forward Equity Partners (formerly Medivate Partners), a private equity firm specializing in cross-border healthcare and life sciences investments. With a particular focus on CGT, Kim's firm has made substantial investments in over fifteen global biotechs and four CDMOs over the past decade. Furthermore, he serves on the boards of SCAI Therapeutics and Riva Therapeutics in San Diego, showcasing his commitment to driving innovation and advancements in the field.

Kim's appointment as CEO marks an exciting milestone for Matica Bio. With his wealth of experience and deep understanding of the industry, the company is well-positioned to thrive amidst the rapidly evolving CGT landscape. Matica Bio's unique approach to CGT manufacturing, exemplified by its purpose-built GMP facility, sets it apart from other players in the CDMO industry. Coupled with its in-house scientific expertise, the company is primed to make significant strides in advancing the field of cell and gene therapies.

This appointment is part of Matica Bio's overall strategy to achieve strategic growth and expand its footprint in the CGT sector. In addition to Kim's arrival, the company plans to enhance its board capacity later this year. These moves reflect Matica Bio's commitment to staying at the forefront of innovation and driving positive change in the industry.

In recent years, Matica Bio has made significant strides in optimizing critical components of its CGT manufacturing processes. By leveraging a fully closed system approach and a 100 percent single-use platform, the company ensures the highest levels of safety and efficiency. Additionally, Matica Bio has invested in advanced analytical capabilities to support the development and manufacturing of CGTs. Furthermore, it has introduced its high-performance proprietary cell line, MatiMax^TM, further solidifying its position as a leader in the field.

Matica Biotechnology, Inc., founded with the mission to deliver breakthrough therapies rapidly and safely, is an industry-leading CDMO specializing in fully integrated cell and gene therapy manufacturing. With their state-of-the-art facility in Texas, Matica Bio's team of experts is dedicated to providing innovative manufacturing solutions to transform the future of healthcare.

As Matica Bio enters this new phase with Paul Kim at the helm, it is poised to unlock the full potential of cell and gene therapies. With a focus on personalized medicine and precision treatments, the company is setting the stage for a brighter future in healthcare. Matica Bio invites you to learn more about its groundbreaking work and commitment to advancing the field of CGTs by visiting its website at [www.maticabio.com](http://www.maticabio.com). Together, let us revolutionize the world of healthcare, one breakthrough therapy at a time.